Cardiff Oncology, Inc.
NASDAQ: CRDF0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Mani Mohindru
- Employees
- 31
- Headquarters
- San Diego, United States
- IPO year
- 2004
- Market cap
- $86.1M
- Website
- https://www.cardiffoncology.com
Loading CRDF…
Loading profile data…Frequently asked questions about CRDF
What does Cardiff Oncology, Inc. (CRDF) do?
Cardiff Oncology, Inc., a clinical-stage biotechnology company, develops novel therapies for the treatment of various cancers in the United States. Its lead drug candidate is Onvansertib, an oral and selective polo-like kinase 1 inhibitor for treating RAS-mutated metastatic colorectal cancer. The company also focuses on the clinical program in i...
Where does CRDF trade?
Cardiff Oncology, Inc. (CRDF) trades on the NASDAQ.
What sector is CRDF in?
Cardiff Oncology, Inc. (CRDF) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Cardiff Oncology, Inc.?
Mani Mohindru is the chief executive officer of Cardiff Oncology, Inc. (CRDF).
Where is Cardiff Oncology, Inc. headquartered?
Cardiff Oncology, Inc. is headquartered in United States.
Does CRDF pay a dividend?
Cardiff Oncology, Inc. (CRDF) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did CRDF go public?
Cardiff Oncology, Inc. (CRDF) completed its initial public offering in 2004.